223 related articles for article (PubMed ID: 14506151)
1. Epigenetic inactivation of RASSF1A in head and neck cancer.
Dong SM; Sun DI; Benoit NE; Kuzmin I; Lerman MI; Sidransky D
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3635-40. PubMed ID: 14506151
[TBL] [Abstract][Full Text] [Related]
2. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.
Horiguchi K; Tomizawa Y; Tosaka M; Ishiuchi S; Kurihara H; Mori M; Saito N
Oncogene; 2003 Oct; 22(49):7862-5. PubMed ID: 14586413
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Clin Cancer Res; 2003 Apr; 9(4):1441-5. PubMed ID: 12684417
[TBL] [Abstract][Full Text] [Related]
6. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
8. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma.
Qiu GH; Tan LK; Loh KS; Lim CY; Srivastava G; Tsai ST; Tsao SW; Tao Q
Oncogene; 2004 Jun; 23(27):4793-806. PubMed ID: 15122337
[TBL] [Abstract][Full Text] [Related]
9. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
[TBL] [Abstract][Full Text] [Related]
11. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer.
Wang SH; Liu NH; Wang J; Bai H; Mao L
Chin Med J (Engl); 2008 Sep; 121(17):1712-21. PubMed ID: 19024105
[TBL] [Abstract][Full Text] [Related]
12. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma.
Carvalho AL; Chuang A; Jiang WW; Lee J; Begum S; Poeta L; Zhao M; Jerónimo C; Henrique R; Nayak CS; Park HL; Brait MR; Liu C; Zhou S; Koch W; Fazio VM; Ratovitski E; Trink B; Westra W; Sidransky D; Moon CS; Califano JA
Cancer Res; 2006 Oct; 66(19):9401-7. PubMed ID: 17018594
[TBL] [Abstract][Full Text] [Related]
13. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
14. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
Hui AB; Lo KW; Kwong J; Lam EC; Chan SY; Chow LS; Chan AS; Teo PM; Huang DP
Mol Carcinog; 2003 Dec; 38(4):170-8. PubMed ID: 14639656
[TBL] [Abstract][Full Text] [Related]
16. Re-expression of RASSF1A by 5-Aza-CdR induced demethylation of the promoter region in human biliary tract carcinoma cells.
Zuo S; Chen Y; Xu L; Tang Q; Zou S
J Huazhong Univ Sci Technolog Med Sci; 2007 Jun; 27(3):281-4. PubMed ID: 17641842
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of the RASSF1A in osteosarcoma.
Lim S; Yang MH; Park JH; Nojima T; Hashimoto H; Unni KK; Park YK
Oncol Rep; 2003; 10(4):897-901. PubMed ID: 12792742
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
20. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]